Day: September 27, 2022

All Podcast Categories
S3-E46.6 - From the Vault: Can Weight Loss From GLP-1s or Double/Triple Agonists Emulate the Effects of Bariatric Surgery in SPLENDOR?

S3-E46.6 – From the Vault: Can Weight Loss From GLP-1s or Double/Triple Agonists Emulate the Effects of Bariatric Surgery in SPLENDOR?

In a review of the 2022 NAFLD Summit, program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Roger Green to discuss the impact of weight change and lifestyle modification in clinical trials while utilizing insights from the bariatric and diabetes fields. This episode From the Vault comes from Season 2, Episode 61.3 where Roger Green, Stephen Harrison, Ali Aminian and Wayne Eskridge discuss how weight loss and GLP-1s or Double/Triple Agonists in relation to SPLENDOR.

S3-E46.5 - Discussing NITs and Final Thoughts on NAFLD Summit

S3-E46.5 – Discussing NITs and Final Thoughts on NAFLD Summit

Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Roger Green, on-site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this final conversation, the group discusses NITs and what will change between now and when this conference convenes next year.

S3-E46.4 - Weight Change and Lifestyle Modification in Clinical Trials

S3-E46.4 – Weight Change and Lifestyle Modification in Clinical Trials

Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Roger Green, on-site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this conversation, the group discusses the impact of weight change and lifestyle modification in clinical trials.

S3 E46.3 - Discussing Clinical Trial Design at the NAFLD Summit

S3 E46.3 – Discussing Clinical Trial Design at the NAFLD Summit

Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Surfer, Roger Green, on-site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this conversation, the group explores issues around clinical trial design, focusing specifically on the value of Phases 2a and 2b and whether improvement in patient self-management during trials is a research artifact or a replication of reality.

S3-E46.2 - NAFLD Summit in Context and Learning from Failed Trials

S3-E46.2 – NAFLD Summit in Context and Learning from Failed Trials

Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Surfer, Roger Green, on site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this conversation, the group contextualizes and compares the NAFLD Summit to other major liver conferences and meetings. The group also assesses Session 9 from Friday, a series of case studies on why trials fail.

S3-E46.1 - Underreported Alcohol Use and Treating Comorbidities

S3-E46.1 – Underreported Alcohol Use and Treating Comorbidities

Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Surfer, Roger Green, on site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this conversation, the group discusses underreported alcohol use in clinical trials and the impact of treating comorbidities on the treatment of NAFLD.

Experience Nudge Learning! Interested in a new way of learning?